加拿大的治疗重新分类从骨质疏松症加拿大2023临床实践指南:曼尼托巴BMD注册表
William D Leslie1, Lisa M Lix2, Neil Binkley3
1Max Rady College of Medicine, University of Manitoba, C5121-409 Tache Avenue, Winnipeg, MB, R2H 2A6, Canada. bleslie@sbgh.mb.ca.
Archives of osteoporosis
|September 7, 2024
概括
2023年加拿大骨质疏松症指南完善了骨质疏松症的治疗建议,影响了以前处于中度风险类别的人. 此更新旨在增加适当的抗骨质疏松药物治疗的使用,并可能减少骨折负担.
科学领域:
- 骨健康和骨质疏松症管理.
- 临床实践指南的演变.
- 用于预防骨折的药物治疗.
背景情况:
- 2010年加拿大骨质疏松症指南为骨质疏松症治疗提供了风险类别.
- 2010年指南的中等风险类别缺乏明确的治疗方向.
- 在2023年的更新中考虑了骨折史,10年重大骨质疏松性骨折 (MOF) 风险,以及随年龄而增加的BMD T-score.
研究的目的:
- 评估2023年加拿大骨质疏松指南对治疗建议的影响.
- 根据2010年和2023年指南对患者分类进行比较.
- 评估从风险类别转向精细治疗指南的影响.
主要方法:
- 分析了79,654名年龄≥50岁的个体,具有基线DXA数据 (1996-2018).
- 根据2010年和2023年指南建议对个人进行分类.
- 治疗资格,预测的10年MOF风险和观察到的MOF风险的比较.
主要成果:
- 2023年的指导方针对2010年中等风险组的33.8%进行了重新分类:13.0%没有治疗,14.4%建议治疗,6.4%建议治疗.
- 在平均7.2年的随访期间,8.0%的人经历了MOF.
- 观察到的10年MOF发病率 (10.5%) 与预测的风险 (10.7%) 非常接近.
结论:
- 2023年加拿大骨质疏松指南增加了推或建议使用抗骨质疏松药物治疗的个体数量,特别是在以前的中度风险组内.
- 这种转变可能导致人口水平骨质疏松性骨折的减少.
- 根据2023年指南新获得治疗资格的个人,骨折风险低于根据2010年高风险类别推接受治疗的人.
关键词:
加拿大加拿大加拿大加拿大加拿大加拿大加拿大临床实践指南 临床实践指南双能X射线吸收度测试是双能X射线吸收度测试.弗拉克斯 (FRAX) 是一个骨折 骨折 骨折 骨折 在骨质疏松症是一种骨质疏松症.更多相关视频
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
8.1K
09:02Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
Published on: January 31, 2025
422
相关概念视频
Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Fractures: Bone Repair
3.0K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
3.0K
